IMNMImmunome Inc.vs its industry peers
A metric-by-metric comparison of Immunome Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMNMEsta | $2.6B#3 | — | 4.4x#1 | 375.4x#2 | -23.2%#2 | 27.5%#1 | -3228.8%#2 | -36.1%#1 | -3451.6%#2 | — | — | — |
| INSM | $21.3B#1 | — | 30.3x#3 | 35.2x#1 | 66.7%#1 | -39.7%#2 | -205.6%#1 | -181.1%#3 | -185.1%#1 | 4#1 | -9.5%#1 | — |
| SMMT | $10.4B#2 | — | 16.5x#2 | — | — | -387.8%#3 | — | -171.4%#2 | — | — | -51.8%#2 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-08-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice